CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...
Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...
USDA Animal and Plant Health Inspection Service (APHIS) announced on January 23, 2025, that it is reinstating its legacy ...
A new study links a particular gene to the origins of spoken language, proposing that a protein variant found only in humans may have helped us develop speech.
Hosted on MSN16h
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...
Most mutations that decreased antibiotic susceptibility were related to specific metabolic pathways. A MIC-increase to ...
AZoLifeSciences on MSN16h
Novel Anti-CRISPR Protein Targets Cas13b RNA NucleaseThere are numerous potential uses for the CRISPR-Cas gene scissors, ranging from antiviral treatments and diagnostics to the ...
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
Hundreds of different species of microbes live in your gut. In the future, one of these might serve a new function: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback